NCT04893226

Brief Summary

This is a randomized, parallel two-arm clinical trial design to study the efficacy of time-restricted feeding on metabolic risk in postmenopausal women, who may be particularly vulnerable to disruption of circadian eating rhythms and the associated metabolic dysfunction. It is hypothesized that time-restricted feeding will improve insulin sensitivity, glucose tolerance, body weight, and other metabolic parameters in metabolically-unhealthy postmenopausal women.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
164

participants targeted

Target at P75+ for not_applicable

Timeline
9mo left

Started Oct 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress86%
Oct 2021Jan 2027

First Submitted

Initial submission to the registry

May 12, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 19, 2021

Completed
5 months until next milestone

Study Start

First participant enrolled

October 19, 2021

Completed
5.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2027

Last Updated

November 19, 2025

Status Verified

November 1, 2025

Enrollment Period

5.3 years

First QC Date

May 12, 2021

Last Update Submit

November 16, 2025

Conditions

Keywords

postmenopauseweightmetabolic riskglucosebody compositionlipidsleepprediabetesfastingcircadianinflammation

Outcome Measures

Primary Outcomes (3)

  • Change in Insulin Sensitivity

    Matsuda index will be assessed by the oral glucose tolerance test (OGTT).

    18 weeks (baseline and post-intervention)

  • Change in Body Mass Index

    Body mass index will be calculated from height and weight.

    18 weeks (baseline and post-intervention)

  • Change in Triglycerides

    Triglycerides will be measured from fasting blood

    18 weeks (baseline and post-intervention)

Secondary Outcomes (4)

  • Change in Hemoglobin A1c

    18 weeks (baseline and post-intervention)

  • Change in C-Reactive Protein

    18 weeks (baseline and post-intervention)

  • Change in Mid-sleep

    18 weeks (baseline and post-intervention)

  • Change in Sleep Fragmentation Index

    18 weeks (baseline and post-intervention)

Study Arms (2)

Control

NO INTERVENTION

Participants in this group will have baseline and post-study data collected, including food timing, activity/sleep data, and metabolic parameters (OGTT, body composition, anthropometric measurements, lipid panel, inflammatory markers). There will be no intervention.

Time-Restricted Feeding (TRF) Group

EXPERIMENTAL

Participants in this group will have baseline and post-study data collected, including food timing, activity/sleep data, and metabolic parameters (OGTT, body composition, anthropometric measurements, lipid panel, inflammatory markers). Subjects in this group will be educated about the health benefits of time-restricted feeding (TRF). Then each subject in the TRF group will self-select a 10-h window during which she will consume all daily calories for 16 weeks.

Behavioral: Time-Restricted Feeding (TRF)

Interventions

Subjects will be educated about the health benefits of time-restricted feeding (TRF). Each subject in the TRF group will self-select a 10 hour (10h +/- 1hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily meals for the duration of the study.

Time-Restricted Feeding (TRF) Group

Eligibility Criteria

Age45 Years - 65 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • postmenopausal women
  • age 45-65 years
  • prediabetic or have at least 2 features of metabolic syndrome

You may not qualify if:

  • on hormone therapy
  • diabetes
  • heart disease
  • alcohol consumption of \>2 drinks per day
  • significant circadian disruption
  • having care-taking responsibilities that significantly affect sleep
  • shift work or irregular lifestyle
  • uncontrolled sleep apnea or other uncontrolled sleep disorder
  • extreme early or late chronotypes
  • significant psychiatric disorders
  • taking ADHD medications
  • diagnosed dysregulated eating behaviors
  • smoking \>5 cigarettes/day or 30 pack-year history
  • participating in formal weight loss program
  • not weight stable

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Kentucky

Lexington, Kentucky, 40536, United States

RECRUITING

MeSH Terms

Conditions

Metabolic SyndromeBody WeightPrediabetic StateFastingInflammation

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsDiabetes MellitusEndocrine System DiseasesFeeding BehaviorBehaviorPathologic Processes

Study Officials

  • Julie S Pendergast, PhD

    University of Kentucky

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Matt Thomas, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

May 12, 2021

First Posted

May 19, 2021

Study Start

October 19, 2021

Primary Completion (Estimated)

January 31, 2027

Study Completion (Estimated)

January 31, 2027

Last Updated

November 19, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations